T akayasu arteritis (TA) is a chronic vasculitis mainly involving the aorta and its main branches, inducing varied events because of occlusive lesions, aneurysmal degenerations, or thrombus formations. 1 TA has been proved to be seen in multiple ethnicities around the world with higher prevalence in Asia. [2] [3] [4] According to a long-term follow-up study published recently, half of patients with TA relapse and experience a vascular complication in 10 years from diagnosis. 3 However, the nonspecific clinical symptoms, varying according to the arteries and related blood supply areas involved, made the diagnosis and activity assessment of TA difficult and often ambiguous.
The diagnosis of TA is often delayed when lesions induced clinical symptoms and related imaging features occurred, associating with poorer prognosis. 5 According to a registry study including 1372 TA patients, disease statuses were severe in patients who registered at ≥1 year after onset. 6 Clinically, TA activity assessment is mainly based on scoring scales of clinical manifestations and nonspecific inflammatory biomarkers, such as erythrocyte sedimentation rate and CRP (C-reactive protein). This approach might ineluctably bring ambiguity and subjectivity. Unfortunately, the use of 18 F-fluoro-Dglucose positron emission tomography (PET)-computed tomography (CT), a valuable tool in characterizing disease activity of TA, is still limited by its high cost and radiation. 7 Moreover, studies about the potentialities of biomarkers, such as PTX (pentraxin)-3, IL (interleukin)-6, MMP (matrix metalloproteinase)-3, showed controversial results. [8] [9] [10] [11] Taken together, these suggested the need of novel biomarkers. In the present study, we used largescale protein arrays and performed further validations in independent cohorts to investigate novel biomarkers for the precisive diagnosis and activity assessment of TA.
METHODS
The article conforms with the Transparency and Openness Promotion Guidelines. The research protocol was approved by the ethics committee of Fuwai Hospital, Beijing Anzhen Hospital, Peking Union Medical College Hospital (PUMCH), and Kailuan General Hospital. Methods are now available in the Data Supplement.
RESULTS

Screening Phase by Using Protein Arrays
First, we used a 440-cytokine protein arrays to screen for potential biomarkers (Figure 1 ). We consecutively enrolled 60 subjects with TA from Fuwai Hospital (Fuwai cohort 1, 29 in active phase, 31 in inactive phase) and 30 healthy controls from Kailuan Community (Kailuan cohort 1). None of the subjects had other autoimmune or inflammatory diseases. We observed no significant difference between TA patients and controls in sex, age, or comorbidities, including dyslipidemia and diabetes mellitus. There existed no significant difference between groups in laboratory test, including levels of red blood cell, platelet, alanine aminotransferase, serum creatinine, and fasting blood glucose, either. However, TA patients had a significant higher incidence in hypertension, a significant lower body mass index and higher levels of white blood cell and neutrophil (Table 1) . Table 2 displayed the clinical characteristics of TA patients that were related to disease activity in the past 3 months before enrollment. Among them, blood pressure elevation, pulse and blood pressure inequality, and central compound nervous system symptoms were significantly different between TA patients in different status (Table 2 ). Figure I in the Data Supplement displayed the distribution of data. Principal component analysis of the proteomics data and scores of samples on the first 2 principal components were shown in Figure II in the Data Supplement and Table I Tables II and III in the Data Supplement) . Among them, cytokines such as TIMP (tissue inhibitor of metalloproteinases)-1, p-cadherin, and MMP-9 significantly increased in TA patients compared with controls ( Figure 2A) . Meanwhile, cytokines such as wnt inhibitory factor 1 significantly decreased in TA patients ( Figure 2B ). The hierarchical clustering of TA and controls based on these 18 cytokines were shown as Figure 3A and Figure III in the Data Supplement.
Comparing TA patients in active and inactive status, we identified another 15 cytokines (adjusted P<0.05 ;  Tables II and IV in the Data Supplement) . Among them, cytokines such as LYVE (lymphatic vessel endothelial hyaluronic acid receptor)-1 and CRP significantly increased in active status ( Figure 2C ), while some other cytokines such as IL-17C, IL-5 Ra, and FLRG (follistatinrelated protein) significantly decreased ( Figure 2D ). The hierarchical clustering of samples based on these 15 cytokines were shown as Figure 3B and Figure III in the Data Supplement. Previous studies showed controversial results in PTX-3 and TA activity. [9] [10] [11] In the present study, we did not find PTX-3 significantly different between active and inactive groups (adjusted P=0.409). The correlations between differentially enriched cytokines were shown in Figure IV in the Data Supplement.
Validation of Potential Biomarkers for TA Diagnosis
Then, we selected cytokines with an area under the curve (AUC) discriminating TA patients and controls over 0.75 in the screening cohorts for further validation ( Figure 1 ). Among them, cytokines with con-centrations beyond detectable thresholds of ELISA in preexperiment were excluded. TIMP-1, MMP-9, IL-6 sR, and P-Cadherin were then validated in new cohorts by using ELISA. We enrolled another 55 TA patients (Fuwai cohort 2) from Fuwai Hospital, which is independent of Fuwai cohort 1 in the screening phase. We also enrolled another 48 individuals from Kailuan Community as controls (Kailuan cohort 2). In Fuwai cohort 2, we found that TIMP-1 (adjusted P=0.001) and P-Cadherin (adjusted P=0.022) were significantly increased in TA patients compared with controls. However, we did not observe significant difference in the concentrations of IL-6 sR (adjusted P=0.604) between 2 groups. The levels of MMP-9 were even lower in TA patients (adjusted P<0.001; Figure 4A ; Table 3 ).
To get an external validation, we enrolled another cohort from Anzhen Hospital, including 29 TA patients (Anzhen cohort). In Anzhen cohort, we also found that TIMP-1 (P<0.001) and P-Cadherin (adjusted P=0.004) significantly increased in TA patients compared with controls. Levels of IL-6 sR between groups were not significantly different in this cohort, either (adjusted P=0.409). However, the levels of MMP-9 were significantly increased in TA patients in Anzhen cohort (adjusted P<0.001; Figure 4B ; Table 3 ).
Combining the above data from different cohorts, the AUC of TIMP-1 and P-Cadherin to discriminate TA patients and controls were 0.790 and 0.660, respectively (Table 3 ; Figure V in the Data Supplement). Based on the Youden index, we defined the appropriate cutoff value for TIMP-1 for TA diagnosis as 221.86 μg/L. According to this cutoff value, the sensitivity, specificity, positive predictive value, and negative predictive value of using TIMP-1 as biomarker for TA diagnosis were 68.0%, 89.58%, 0.92, 0.61, respectively. This suggested TIMP-1 could be a specific biomarker for TA diagnosis.
Validation of Potential Biomarkers for TA Activity Classification
Also, we selected cytokines with AUC discriminating TA patients in active and inactive status over 0.75 in the screening cohorts for further validation (Figure 1 ), among which cytokines with concentrations beyond detectable thresholds of ELISA in preexperiment were excluded as well. Then, we validated CD (cluster of differentiation) 99, CA15-3, LYVE-1, and legumain in independent cohorts by using ELISA. In Fuwai cohort 2 (31 TA patients in active status and 24 TA patients in inactive status), we found that CD99 (adjusted P=0.012), CA15-3 (adjusted P=0.021), and LYVE-1 (adjusted P=0.015) were significantly increased in TA patients in active status compared with those in inactive status. Levels of legumain were not significantly different between groups (adjusted P=0.245; Figure 4C ; Table 4 ).
To get an external validation, we enrolled another TA patients cohort from PUMCH (27 TA patients in active status and 27 TA patients in inactive status). However, in PUMCH cohort, none of these 4 cytokines were significantly differentially enriched between TA patients in active and inactive status (adjusted P>0.05; Figure 4D ; Table 4 ). These results suggested an unreliability of using a single cytokine as the biomarker for TA activity classification. Values are mean±SD, median (first quartile and third quartile), or n. ALT indicates alanine aminotransferase; AS, ankylosing spondylitis; BMI, body mass index; CREA, serum creatinine; DBP, diastolic blood pressure; FBG, fasting blood glucose; HGB, hemoglobin; HR, heart rate; NEUT, neutrophil; PLT, platelet; RA, rheumatoid arthritis; RBC, red blood cell; SBP, systolic blood pressure; SLE, systemic lupus erythematosus; TA, Takayasu arteritis; and WBC, white blood cell.
*50 of 60 subjects in the TA group were available to get BP values, while the other 10 subjects in TA group had a BP loss in both upper limbs. In addition, BP was derived from the brachial artery that might underestimate true systemic BP in subjects with subclavian artery stenosis. *These abnormalities were newly onset or worsen during the last 3 months before enrollment.
†BP elevation, systolic BP >140 mm Hg, or diastolic BP >80 mm Hg. ‡CNS symptoms indicates dizziness, vertigo, seizures, syncope, or stroke. §The usage of these medications was on present or during the last 1 months before enrollment.
Precisive TA Activity Classification Based on Multiple Cytokines
Considering these, we further explored the potentiality of using models based on multiple biomarkers for TA activity classification. We divided the protein array data into a training set (70%) and a test set (30%) by random sampling without replacement. First, we performed a variable selection process based on the data in the training set (18 TA patients in active status and 24 TA patients in inactive status). The approach adopted in this process was the combination of random forest-based recursive feature elimination (RFE) and least absolute shrinkage and selection operator (LASSO) regression. According to the RFE with random forests, we identified 11 optimal biomarkers, including CA (cancer antigen) 125, FLRG, IGFBP (insulin-like growth factor-binding protein)-2, IL-17C, CA15-3, IL-5 Ra, GROa (growth-regulated alpha protein), Legumain, LYVE-1, ULBP (UL16-binding protein)-2, and CD99. Among them, the top 5 variables were CA125, FLRG, IGFBP-2, IL-17C, and CA15-3 ( Figure 5A ; Table V in the Data Supplement). According to LASSO regression model, we identified 11 biomarkers, including TRAIL R (tumor necrosis factor-related apoptosis-inducing ligand receptor) 4, CA125, CA15-3, CRP, GROa, Leptin R, FLRG, ULBP-2, CD99, LYVE-1, and IGFBP-2 ( Figure 5B and 5C; Table VI in the Data Supplement). The overlapping biomarkers selected by using these 2 methods were CA125, FLRG, IGFBP-2, CA15-3, GROa, LYVE-1, ULBP-2, and CD99. Strong correlations existed across CA15-3, LYVE-1, and IGFBP-2(adjusted P<0.05, 0.5 ≤ |r| <1). .05) . B, Cytokines significantly decreased in TA patients compared with controls adjusted P<0.05). C, Cytokines significantly increased in TA patients in active status compared with TA patients in inactive status (adjusted P<0.05). D, Cytokines significantly decreased in TA patients in active status compared with TA patients in inactive status (adjusted P<0.05). *P<0.05; **P<0.01; and ***P<0.001. CA indicates cancer antigen; CD, cluster of differentiation; CRP, C-reactive protein; FLRG, follistatin-related protein; GROa, growth-regulated alpha protein; IGFBP, insulin-like growth factor-binding protein; IL, interleukin; LYVE, lymphatic vessel endothelial hyaluronic acid receptor; MCSF R, macrophage colony-stimulating factor receptor; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; TA, Takayasu arteritis; TIMP, tissue inhibitor of metalloproteinases; TRAIL R, tumor necrosis factor-related apoptosis-inducing ligand receptor; ULBP, UL16-binding protein; and WIF, wnt inhibitory factor.
Pearson correlations and corresponding adjusted P values between these 8 biomarkers.
Based on data of these 8 biomarkers in the training set, we built a logistic regression model for TA activity classification (Table 5 ). Applying the model in the training set yielded an AUC of 1 for discriminating TA active and inactive status. Then, we applied this logistic regression model in the test set (11 subjects in active status and 7 subjects in the inactive status), which was independent of the training set. Surprisingly, all of the 7 subjects in inactive status in the test set were correctly predicted of not having a disease activation. Nine of the 11 subjects in active status were also correctly predicted. These results yielded a sensitivity of 81.82%, a specificity of 100%, a positive predictive value of 1, and a negative predictive value of 77.78% (AUC=0.909) for TA activity classification in the test set ( Figure 5D ). 
DISCUSSION
In the first phase of the present study, we used largescale protein arrays to screen for potential biomarkers, which might help us avoid the limitation brought by the prior knowledge. 12 Through this phase, we identified 18 potential biomarkers for TA diagnosis and another 15 for activity classification. Then, we validated certain cytokines in independent cohorts by using ELISA. The results from the validation phase suggested TIMP-1 as a useful biomarker for TA diagnosis, while unreliable to use a single biomarker for TA activity assessment. In view of this, we further built an efficient model for TA activity classification based on 8 key cytokines selected by the random forest-based recursive feature selection and the LASSO regression.
For TA diagnosis, we found that TIMP-1 could be a specific biomarker that a cutoff value of 221.86 μg/L could provide a specificity of 89.58% and a positive predictive value of 0.92. TIMP-1, one of the members of TIMPs, is a natural inhibitor of MMPs, playing important roles in regulating ECM (extracellular matrix) turnover and subsequently affected the proliferation, migration, and apoptosis of vascular cells. 13, 14 Although the pathogenesis of TA is still unclear, TA as an inflammatory fibrosing arteritis with an autoimmune basis has already been strongly suggested. 15 This suggested possible relationships between the biomarker and the pathogenesis of TA, which should be further investigated in follow-up studies. Previous studies have also found TIMP-1 as a biomarker for psoriasis, liver fibrosis, and cancers. [16] [17] [18] When these diseases were excluded, raised levels of TIMP-1 over 221.86 μg/L might be supportive for the clinical diagnosis of TA.
For TA activity classification, we observed an inconsistence in different cohorts in the validation phase, suggesting an unreliability to use a single biomarker for TA diagnosis. Considering this, we further explored the potentiality of multiple-biomarker based model for TA activity classification. We performed the variable selection process by using the combination of random forest-based RFE and LASSO regression. Recursive feature elimination applied with random forest or support vector machine was an automatic machine-learning method for identifying the optimal features for building a good model. 19, 20 LASSO regression is a classic regression method that is often used for the dimension reduction of high-dimensionality data and select the essential variables. 21 To make the model more interpretable in clinical contexts, we used the logistic regression as the method which is more familiar to physicians other than machine-learning algorithms. The model was built based on data in the training set and showed a surprisingly good performance on the independent test set with a specificity of 100%, a positive predictive value of 1 and an AUC reaching 0.909. Cytokines included in the TA activity classification model were CA125, FLRG, IGFBP-2, CA15-3, GROa, LYVE-1, ULBP-2, and CD99. Among them, cytokines such as ULBP-2 increased in TA patients in active status. Previous studies have suggested that ULBP-2, as an MHC (major histocompatibility complex) class I-related molecule, could activate multiple pathways, mediating natural killer cell cytotoxicity via binding the NKG (natural killer group) 2D receptor. 22 Mechanisms into the changes in ULBP-2 along with other cytokines and the disease activity of TA should also be further studied.
Admittedly, there were some limitations of this study. First, the increment value could not be assessed because the pathological examination of biopsy tissues, the golden standard for the diagnosis and activity assessment, were lacking. However, the risks of arterial biopsy in TA outweigh any benefit. Therefore, the diagnosis and disease status assessment of these diseases such as TA are usually made based on international scoring scales. In this study, to ensure the accuracy as much as possible, the combination of different scoring scales was used; for TA diagnosis, the combination of the ACR 1990 criteria and Ishikawa criteria; for TA activity classification, the combination of National Institutes of Health criteria, ITAS2010, and ITAS-A. To reduce the possible subjectivity brought by using these mainly clinical manifestationbased scoring scales, we had 2 experienced physicians performed the diagnosis and activity assessment backto-back, and only the consensus of them was adopted. Studies including PET evaluation and biomarkers validation in larger TA population will be further performed. Second, for economic consideration, instead of reusing protein arrays to test samples from other cohorts, the logistic regression model for TA activity was built and tested by random sampling the data into a training set and an independent test set. This strategy is often used by researchers when lacking another validating cohort. However, lacking external validation from other centers with possibly different sample process and subjects with possibly different demographic characteristics might make the study cohort without enough heterogeneity to improve the models' generalizability.
Taken together, in the present study, we identified multiple cytokines differentially enriched across controls and TA patients in active and inactive status by using large-scale protein arrays. Through validating potential biomarkers in different cohorts by using ELISA, we identified TIMP-1 as a specific biomarker for TA diagnosis with a cutoff value of 221.86 μg/L. Meanwhile, we found that using a cytokine as the biomarker for TA activity assessment was unreliable. So, we further built and evaluated a logistic regression model based on 8 cytokines for TA activity classification, which could precisely differentiate TA subjects in active and inactive status with an AUC of 0.909 in the test set. These findings are of great significance for clinical practice in aiding the precise diagnosis and activity classification of TA. Moreover, considering the biological functions of the identified biomarkers, these findings could be fundamental for further investigations on the pathogenesis of this disease. Also, considering that biological-targeted treatment including the TNF (tumor necrosis factor)-α antagonists and tocilizumab has been validated to have efficacy in TA, our findings might aid the research and development of novel biological-targeted treatment in the future. 23 Follow-up studies are needed to further validate the generalizability of the biomarkers in larger populations, to further investigate the role of these bio- 
